Revospirone

This classification denotes an anxiolytic with the molecular formula C18H21N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X8764TW2J, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(3-(4-(2-pyrimidinyl)-1-piperazinyl)propyl)-, 1,1-dioxide but generally known as revospirone, which bears US NIH Compound Identifier 72024. European Medicines Agency schedules Revospirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10296MIG. The term REVOSPIRONE is an International Non-Proprietary Name. REVOSPIRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule revospirone under HS 29341000 and SITC 51579. As of Q4 2014, REVOSPIRONE remains the US FDA Preferred Term for this commodity. Revospirone bears US NLM identifiers UMLS ID C2699076 and NCI Concept Code C76509. SMILES: S1(=O)(=O)N(CCCN2CCN(CC2)C2NCCCN2)C(=O)C2C1CCCC2.